间质性肺疾病患者接受姑息性放疗伴或不伴肺部照射的影响
回顾性分析103例间质性肺疾病患者接受姑息性放疗,中位影像随访88天、生存随访144天。多因素分析显示肺纤维化评分≥3分(HR 2.16)和肺部照射(HR 3.82)是≥3级急性加重或急性肺损伤/放射性肺炎的显著危险因素。肺纤维化评分≥3分且接受肺部照射者100天累积发生率为37.5%,且全部为5级。
要点
- 肺纤维化评分≥3分(HR 2.16)和肺部照射(HR 3.82)是≥3级AE-ALI/RP的显著危险因素。
- 肺纤维化评分≥3分且接受肺部照射者100天累积发生率为37.5%,全部为5级。
- 肺纤维化评分≥3分未接受肺部照射者100天累积发生率为4.8%。
核心结论
- 高肺纤维化评分和肺部照射是≥3级AE-ALI/RP的显著危险因素。
- 即使剂量相对较低,当肺纤维化评分高时,姑息性肺部照射带来极高的AE-ALI/RP风险。
研究设计与样本
- 回顾性分析2011年1月至2022年1月期间接受姑息性放疗的间质性肺疾病患者数据,共103例。
- 中位影像随访时间为88天(范围2-1440天),中位生存随访时间为144天(范围8-1441天)。
- 采用单因素和多因素分析评估与≥3级AE-ALI/RP相关的因素。
主要发现
- ≥3级AE-ALI/RP的中位发生时间为72天(范围5-206天)。
- 多因素分析中,肺纤维化评分≥3分与≥3级AE-ALI/RP显著相关(HR 2.16,95%CI 1.36-3.43,p<0.01)。
- 多因素分析中,肺部照射与≥3级AE-ALI/RP显著相关(HR 3.82,95%CI 1.01-15.73,p=0.04)。
- 接受肺部照射的患者中,100天生存率为56.8%,≥3级AE-ALI/RP的100天累积发生率为13.7%。
- 肺纤维化评分≥3分且接受肺部照射的患者中,≥3级AE-ALI/RP的100天累积发生率为37.5%,所有发生≥3级AE-ALI/RP的患者均为5级。
关键数值与推荐
- 肺纤维化评分≥3分:≥3级AE-ALI/RP的HR为2.16(95%CI 1.36-3.43,p<0.01)。
- 肺部照射:≥3级AE-ALI/RP的HR为3.82(95%CI 1.01-15.73,p=0.04)。
- 肺纤维化评分≥3分且接受肺部照射者100天累积发生率为37.5%,肺纤维化评分≥3分未接受肺部照射者为4.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Acute exacerbations or acute lung injury, including radiation pneumonitis (AE-ALI/RP) of interstitial lung disease (ILD), has a fatal prognosis. We evaluated the risk of palliative-intent radiotherapy (RT), with or without lung irradiation, for AE-ALI/RP of ILD. MATERIALS AND METHODS: The data of patients with ILD who received palliative-intent RT between January 2011 and January 2022 were retrospectively reviewed. Factors associated with AE-ALI/RP grade ≥ 3 were assessed using univariate and multivariate analyses. RESULTS: One hundred and three patients were examined, with median imaging and survival follow-up times of 88 (2-1440) and 144 (8-1441) days. The median time to onset of AE-ALI/RP grade ≥ 3 was 72 (5-206) days. In multivariate analysis, a higher pulmonary fibrosis score (PFS ≥ 3) (hazard ratio, HR: 2.16; 95% confidence interval, CI: 1.36-3.43; p < 0.01) and lung irradiation (lung-RT) (HR: 3.82; 95% CI: 1.01-15.73; p = 0.04) were significant factors for AE-ALI/RP grade ≥ 3. In patients who received lung-RT, the 100-day survival rate and cumulative incidence of AE-ALI/RP grade ≥ 3 were 56.8% and 13.7%, respectively. In patients with PFS ≥ 3 and who underwent lung-RT, the 100-day cumulative incidence of AE-ALI/RP grade ≥ 3 was 37.5%; all patients with AE-ALI/RP grade ≥ 3 had grade 5. In patients with PFS ≥ 3 without lung-RT, the 100-day cumulative incidence of AE-ALI/RP grade ≥ 3 was 4.8%. CONCLUSION: High PFS and lung-RT are significant risk factors for AE-ALI/RP grade ≥ 3. Even with relatively low doses, palliative-intent lung-RT carries an extremely high risk of AE-ALI/RP when PFS is high.
引用
- Makita K, Hamamoto Y, Kanzaki H, et al. Impact of palliative radiotherapy with or without lung irradiation in patients with interstitial lung disease. Radiother Oncol. 2023. PMID: 36963439. doi:10.1016/j.radonc.2023.109636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。